Sanofi Sees Booster Role For Covid Vaccine After Solid But Underwhelming Results
Lower Efficacy In Older Adults
Once expected to play a key role in beating COVID-19, Sanofi and GSK now see their vaccine as most likely to be used as a booster.
You may also be interested in...
Availability of emergency authorization route in US depends upon lack of 'adequate, approved and available alternatives,' but as more vaccines make their way through the BLA process sponsors may find the EUA door slowly closing.
Sanofi and GSK, which are in the middle of Phase III global trials for their COVID-19 vaccine candidate, plan to test the contender against all variants of concern including the highly contagious Delta variant, Scrip has learned. Meanwhile, Pfizer/BioNTech is looking at a booster to combat lower efficacy/effectiveness against this variant.
The company is focusing on new technologies, including mRNA, and expects the vaccines business to deliver a high single-digit sales CAGR over the next five years.